

27 - 28 October 2015

[www.pharmaprocessforum.com](http://www.pharmaprocessforum.com)

The Forum features a large trade show area and an attractive panel of speakers

## PharmaProcess Forum analyses the future challenges that the pharma sector needs to tackle

**Issues such as setting up personalized medicines to treat certain diseases such as cancer; the fight against the sale of counterfeit medicines; the different viewpoints of the United States and the European Union regarding the framework for regulating the manufacture and commercialization of medicines; and the latest trends in the design of manufacturing plants are some of the future challenges that will be discussed at this second edition of PharmaProcess Forum, the international meeting for the pharmaceutical industry which takes place on 27 and 28 October at the Montjuïc Exhibition and Conference Centre.**

The PharmaProcess Forum has become the best platform for transferring knowledge in the pharmaceutical sector, with a programme of conferences based around four main themes for discussion and reflection: Regulation and Development, Operations, Business Development and Good Distribution Practices (GDPs). Almost 70 national and international speakers, over 300 delegates and more than 1,500 professional visitors will be taking part in the second edition of the event. Some of the respected experts speaking at the event include Dr Manel Esteller, the director of Cancer Epigenetics and Biology at the Bellvitge Biomedical Research Institute (IDIBELL), and Belén Escribano, the head of the Department of Medicine Inspection and Control at the Spanish Agency for Medicines and Medical Devices (AEMPS), amongst others.

The Forum also has a large trade show area where nearly 45 leading companies in the sector – including Airex, Codols, Festo, Iris and Telstar, amongst others – will be presenting their new products and looking to establish business agreements. The event offers exhibitors the chance to take part in a Project Presentation where they can present all kinds of projects in search of the right suppliers for subsequent industrial and commercial development, as well as Industry Sessions where they can present their success stories.

The event also offers exhibitors and visitors at PharmaProcess Forum an exclusive look at the facilities of Almirall Laboratories and the Barcelona Biomedical Research Park, a limited-seating lunch with the speakers and members of the International Advisory Council at a 'Meet the Professor' session, and the chance to take part in various B2B meetings.

To design an attractive event that addresses the sector's needs, PharmaProcess Forum was counselled by the International Advisory Board (IAB), comprising six leading representatives from the international pharmaceutical industry, who worked closely with the Scientific Committee in selecting the scientific content.

In the space of just two editions, the Forum organized by Fira de Barcelona has won the support of the most representative entities in the sector, such as the Spanish Association of Industrial Pharmacists (AEFI), the Spanish Generic Medicines Association (AESEG), the Spanish Association of Refined Chemical Manufacturers (AFAQUIM) and the Catalan Association of Biotechnology Companies (Catalonia Bio).

**Barcelona, October 2015**

**Eduard Pérez Moya**

(+34) 93 233 21 66

[eperezm@firabarcelona.com](mailto:eperezm@firabarcelona.com)

**From 27 to 28 October 2015**  
[www.pharmaprocessforum.com](http://www.pharmaprocessforum.com)

Research in this setting is up 12% in comparison with 2013.

## **In 2014, the pharmaceutical industry invested over 220 million euros in biotechnology**

The survey on R&D activities, conducted annually by Farmaindustria, highlights the Spanish pharmaceutical industry's interest in biotech research. In 2014, companies in the Spanish pharmaceutical sector invested a total of 224 million euros in biotechnology, an increase of 12% in relation to the figure for 2013. In this regard, biotechnological research accounts for 23.6% of the total amount that the Spanish pharmaceutical sector devotes to Research and Development (R&D).

And last year, the Spanish pharmaceutical industry invested a total of 950 million euros in R&D, a figure which represents an increase of 2.4% with regard to 2013, and which shows that, after three consecutive years of downturns resulting from the financial crisis, the sector has started to grow again.

According to this study, in 2014 Spanish pharmaceutical companies committed a total of 382 million euros to research contracts with hospitals, universities and public centres, which represents an increase of 1.5% over 2014, accounting for 41% of total R&D in the Spanish pharmaceutical industry. Farmaindustria believes that "these collaborations are essential for research into new drugs and for scientific development".

In respect of the investment made in the sectoral setting itself, companies earmarked 568 million euros for R&D, 59% of the total for all investment, the leading community being Catalonia, with 45% of all investment, followed the Community of Madrid with 43%.

Farmaindustria, the Spanish Business Association for the Pharmaceutical Industry, comprises a total of 187 laboratories (115 international and 72 Spanish), which represents practically all prescription medicines sales in Spain (82%). The Spanish pharmaceutical industry generates 40,000 jobs directly, and is indirectly responsible for a further 160,000.

**Barcelona, October 2015**

**Eduard Pérez Moya**  
(+34) 93 233 21 66  
[eperezm@firabarcelona.com](mailto:eperezm@firabarcelona.com)



27–28 October 2015  
www.pharmaprocessforum.com

International Advisory Board to collaborate in selection of forum content

## PharmaProcess creates advisory board of prestigious members of the pharmaceutical industry

**PharmaProcess Forum, the first forum held on the subject in Europe, has established an advisory council, the International Advisory Board (IAB), made up of six major representatives of the international pharmaceutical industry, who will collaborate with the organisers in the selection of scientific content for the forum, which is set to hold its second edition in October 2015 at the Palacio de Congresos of the Montjuïc venue.**

The PharmaProcess International Advisory Board held its first meeting in Barcelona to get underway with the design of the format and scientific content of the forum, and was attended by forum president, Ton Capella; director, Pilar Navarro; and scientific committee coordinator Santi Alsina.

The International Advisory Board is made up of:

Frans Maas, vice president of GEA Pharma Systems (Belgium)

Koji Kawasaki, president of AIREX (Japan)

Antonio Buendía, head of Manufacturing Process Control at NOVARTIS (Switzerland)

Daniel Lachapelle, president of the Processes and Industry Division of FOSTER WHEELER (Canada)

Norm Medeiros, executive director of SANOFI PASTEUR (USA)

Raúl Díaz Varela, vice president of INDUKERN Group (Spain)

The members of the IAB consider Barcelona to be the ideal place for a 'global pharmaceutical industry event', according to Daniel Lachapelle. For Lachapelle, therefore, 'it is essential to have a high-level international scientific programme'. Norman Medeiros stressed that 'it is very important to combine the commercial and congressional aspects'. In this respect, Frans Maas stated that the pharmaceutical sector requires 'a global vision' that deals with all the elements in its value chain from 'the initial process to regulatory issues'. For his part, president Ton Capella is of the opinion that 'the Barcelona brand and the expertise of Fira de Barcelona' will enable PharmaProcess to become 'a global forum in the not-too-distant future'.

Along with the IAB, PharmaProcess Forum has the organisational support of its scientific committee, made up of national industry professionals and members of Pharmaceutical Licensing Group Spain (PLGS), an association that brings together and supports those who work in business development, licensing and strategic planning in the Spanish pharmaceutical and biotech industry. PharmaProcess Forum 2015 is organised in three areas: Development, Business Development and Operations, with Biopharmatech as a common subject matter, in which new pharmaceutical products born of biotechnology will be the topic of debate.

**Barcelona, October 2015**

**Eduard Pérez Moya**  
(+34) 93 233 21 66  
[eperezm@firabarcelona.com](mailto:eperezm@firabarcelona.com)

27 – 28 October 2015

[www.pharmaprocessforum.com](http://www.pharmaprocessforum.com)

**Interview with Ton Capella, president of Azbil Telstar and PharmaProcess**

## **‘PharmaProcess provides a response to the questions being asked by the sector today’**

**Ton Capella is president and CEO of Azbil Telstar, a company based in Terrassa with a strong international presence. With a degree in Industrial Engineering from the Universitat Politècnica de Catalunya - BarcelonaTech (UPC) Ton Capella chairs the Organizing Committee of PharmaProcess which will be held for the second time in October 2015.**

**Question: You are chairman again of the Organizing Committee of PharmaProcess, which is being held for the second time. What’s your general overview of the first edition? What changes will there be in 2015 compared to 2013?**

Our intention is for PharmaProcess to become an international benchmark in the sector in the medium to long term by providing a panel of top-level speakers and taking a very international approach. In this respect, I think the first edition served to put us on this path and to be honest it was a great success, as we exceeded our initial forecasts. But I believe we need to keep working to make PharmaProcess grow and become an event with truly international scope. For this reason, as a brand new organizational feature, we’ve put together an advisory board of six leading representatives of the worldwide pharmaceutical industry which will be the PharmaProcess International Advisory Board.

**What will be the tasks of this new PharmaProcess Advisory Board? And what about the Scientific Committee that worked with you on organizing the first show?**

For us, it’s a matter of great pride that such renowned members of the pharmaceutical community have been willing to collaborate on designing the scientific content of PharmaProcess. The International Advisory Board is made up of Frans Maas, vice-president of Sales and Marketing at GEA Pharma Systems (Belgium); Koji Kawasaki, president of AIREX (Japan); Antonio Buendía, head of Manufacturing Process Control at NOVARTIS (Switzerland); Daniel Lachapelle, president of the Process and Industrial Division at FOSTER & WHEELER (Canada); Norm Medeiros, executive director of SANOFI PASTEUR (USA); and Raúl Díaz Varela, vice-president of INDUKERN Group (Spain). The contributions of all these experts will enable us to create a really high calibre event thanks to their global vision of the sector. Indeed, we’ve already had a working meeting with them and we’re very happy with their level of commitment to our project, steering us along the lines we need to be following.

With regard to the Scientific Committee, which is a key element in the success of PharmaProcess, and with which we work very closely, we’ve decided to enlarge it with the inclusion of some well-known individuals who will help to improve the quality of our event. These people include Santi Alsina as scientific director, and representatives of associations and companies such as the Spanish

Industrial Pharmacists' Association (AEFI), BioCat, Farmaindustria, Reig Jofre Group, Almirall, Esteve and Telstar, as well as the PLGS, CINFA and PDA.

In all honesty, I believe that this is another sign of the pharmaceutical industry's firm commitment to our event. The purpose of the Scientific Committee is to orchestrate the directives issued by the Advisory Board into specific actions.

**You are the president of one of the most international Spanish companies in the sector and you're also committed to the greater internationalization of PharmaProcess. Does this mean that the market is global rather than local?**

Absolutely, I believe that our target market from the perspective of both our company and PharmaProcess is the world. In this respect, bearing in mind that Azbil Telstar is a supplier of technology and services for the health and life sciences sector, it seems obvious to me that internationalization is the only route for growth. And I feel the same about the consolidation of PharmaProcess. Having said that, I don't think that internationalization on its own is enough, because I also think it has to go hand-in-hand with a firm commitment to innovation. This is the formula we apply in our company and I believe it's a successful one. I think this is a policy that Fira de Barcelona also follows and we're doing the same with our event.

**Finally, what message would you like to send to the participants in PharmaProcess 2015?**

I would ask them to participate actively. So that their suggestions and input can help PharmaProcess successfully move forward to truly become an international benchmark event. In this respect, I think PharmaProcess provides a response to what the sector, on an international level, was looking for.

**Barcelona, October 2015**

Eduard Pérez Moya  
(+34) 93 233 21 66  
[eperezm@firabarcelona.com](mailto:eperezm@firabarcelona.com)